CVSC Cardiovascular Sciences Inc (CE)

ORLANDO, FL announced that the recent funding event, in association with its move into the next stage of the development of its primary technology, actually represents a step ahead of where it planned to be. The Company is developing its technology with the University of Central Florida in Orlando. In its first year, the plan was to develop a second-generation material that is designed to prevent post-surgical adhesions, complications from which can be devastating.

Soon after that research began, Dr. Kevin Belfield, the Principle Investigator and Chairman of the UCF Department of Chemistry, along with Dr. Larry Hooper, the Company's CEO, made application to the High Tech Corridor Council program for a grant. Their project was awarded an initial $100,000 to expand the scope of the research.

"This allowed us to move more quickly into some of the follow-up studies that were originally planned for a separate stage," explains the Company's CEO. He goes on to explain that this included many of the in vitro degradation tests. "Since this material is meant to degrade and be resorbed into the body, it is important to characterize the rate of degradation, the change of the physical properties during this process and the nature of the resultant degradation products." By moving these studies up, a second-generation material was produced and characterized at least 4 to 6 months earlier than it would have if it had been relegated to a separate project.

"In addition," Dr. Hooper hastens to add, "with the additional funds provided by the High Tech Corridor Council grant, we were able to purchase laboratory-based equipment that allows us to package and sterilize our material for use in animal trials." Without that, this step would likely be outsourced, using up valuable capital and delaying the development further. This alone will allow the company to really hit the ground running as it moves into this next phase of development of its proprietary technology.

About Cardiovascular Sciences

Cardiovascular Sciences, Inc. is an advanced medical device company which is developing a novel technology platform to address the problem of post-surgical and post-traumatic adhesions. Adhesions and the complications of adhesions are a significant problem worldwide for a wide range of specialists, including general surgeons, cardiothoracic surgeons, orthopedic, plastic, and ophthalmologic and otolaryngology specialists to name just some of them. In addition, the veterinary field has a tremendous need for a product that can prevent similar problems in a wide variety of animals.

The Company's unique materials and processes promise a more cost-effective and decidedly more efficient and capable means to deal with a problem that has been so devastating to so many. Current sponsored research at the University of Central Florida (UCF) and previously at other institutions indicate that The Company is on the right path and progressing well.

In addition to the anti-adhesion technology, The Company owns technology in a variety of other areas, including thrombo-resistant coatings, enhanced intra-arterial balloon pumping catheters, cell engineered vascular tissues, and a method for improved recovery of the heart following cardioplegia. This yields a diversified portfolio with projects in various stages of development. www.cvsciences.org

Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks, and uncertainties and actual results could differ from those discussed. This material is information only and is not an offer or solicitation to buy or sell the securities.

For more information contact: Cardiovascular Sciences Investor Relations 800-858-7502 ir@cvsciences.org

Cardiovascular Sciences (CE) (USOTC:CVSC)
Historical Stock Chart
From Jan 2025 to Feb 2025

Cardiovascular Sciences (CE) (USOTC:CVSC)
Historical Stock Chart
From Feb 2024 to Feb 2025